Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profiling

Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia

(2021) Marisa J. L. Aitken et al.   Journal of Hematology & Oncology

Multiplex accurate sensitive quantitation (MASQ) with application to minimal residual disease in acute myeloid leukemia

(2020) Andrea B Moffitt et al.   NUCLEIC ACIDS RESEARCH

Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia

(2020) Robert P. Hasserjian et al.   BLOOD

Cytogenetic risk score maintains its prognostic significance in AML patients with detectable measurable residual disease undergoing transplantation in remission: On behalf of the acute leukemia working party of the European society for blood and marrow transplantation

(2020) Arnon Nagler et al.   AMERICAN JOURNAL OF HEMATOLOGY

Measurable Residual Disease in Acute Myeloid Leukemia Using Flow Cytometry: A Review of Where We Are and Where We Are Going

(2020) Caroline Dix et al.   Journal of Clinical Medicine

Acute Myeloid Leukemia Measurable Residual Disease Detection by Flow Cytometry in Peripheral Blood Versus Bone Marrow

(2020) Colin Douglas Godwin et al.   BLOOD

How we use molecular minimal residual disease (MRD) testing in acute myeloid leukaemia (AML)

(2020) Richard Dillon et al.   BRITISH JOURNAL OF HAEMATOLOGY

Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia

(2020) Nicholas J. Short et al.   JAMA Oncology

Delineation of target expression profiles in CD34+/CD38− and CD34+/CD38+ stem and progenitor cells in AML and CML

(2020) Harald Herrmann et al.   Blood Advances

A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia

(2019) Renato Bassan et al.   HAEMATOLOGICA

NGS‐Defined Minimal Residual Disease Before Stem Cell Transplantation Predicts Acute Myeloid Leukemia Relapse

(2019) Richard D. Press et al.   AMERICAN JOURNAL OF HEMATOLOGY

Can we incorporate MRD assessment into clinical practice in AML?

(2019) Gert Ossenkoppele et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Utility of Immunophenotypic Measurable Residual Disease in Adult Acute Myeloid Leukemia—Real-World Context

(2019) Nikhil Patkar et al.   Frontiers in Oncology

GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia

(2019) Adriano Venditti et al.   BLOOD

Measurable Residual Disease Monitoring in Acute Myeloid Leukemia with t(8;21)(q22;q22.1): Results of the AML Study Group

(2019) Frank G. Rücker et al.   BLOOD

Quality of Response in Acute Myeloid Leukemia: The Role of Minimal Residual Disease

(2019) Maurillo et al.   Cancers

Leukemia‐associated immunophenotypes subdivided in “categories of specificity” improve the sensitivity of minimal residual disease in predicting relapse in acute myeloid leukemia

(2019) Giovanni Rossi et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

The minimal that kills: Why defining and targeting measurable residual disease is the “Sine Qua Non” for further progress in management of acute myeloid leukemia

(2019) Jan Philipp Bewersdorf et al.   BLOOD REVIEWS

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party

(2018) Gerrit J. Schuurhuis et al.   BLOOD

Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia

(2018) Maja Rothenberg-Thurley et al.   LEUKEMIA

Measurable residual disease (MRD) monitoring by NGS before allogeneic hematopoietic cell transplantation in AML

(2018) Felicitas Thol et al.   BLOOD

The emerging role of measurable residual disease detection in AML in morphologic remission

(2018) F. Buccisano et al.   SEMINARS IN HEMATOLOGY

Minimal/Measurable Residual Disease Monitoring in NPM1-Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and Perspectives

(2018) Fabio Forghieri et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Precision oncology for acute myeloid leukemia using a knowledge bank approach

(2017) Moritz Gerstung et al.   NATURE GENETICS

Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia

(2017) Donald A. Berry et al.   JAMA Oncology

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

(2016) Hartmut Döhner et al.   BLOOD

DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling

(2016) Olga A Guryanova et al.   NATURE MEDICINE

Assessment of Minimal Residual Disease in Standard-Risk AML

(2016) Adam Ivey et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genomic Classification and Prognosis in Acute Myeloid Leukemia

(2016) Elli Papaemmanuil et al.   NEW ENGLAND JOURNAL OF MEDICINE

Optimizing sparse sequencing of single cells for highly multiplex copy number profiling

(2015) Timour Baslan et al.   GENOME RESEARCH

Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900

(2012) M. Gonen et al.   BLOOD

Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia

(2012) Jay P. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia

(2011) F. Buccisano et al.   BLOOD

Tumour evolution inferred by single-cell sequencing

(2011) Nicholas Navin et al.   NATURE

Surrogate marker profiles for genetic lesions in acute leukemias

(2010) Elisabeth Paietta   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia

(2010) F. Buccisano et al.   BLOOD

Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial

(2010) Jeffrey E Rubnitz et al.   LANCET ONCOLOGY

Identification of Therapeutic Targets for Quiescent, Chemotherapy-Resistant Human Leukemia Stem Cells

(2010) Y. Saito et al.   Science Translational Medicine

Interleukin-2 receptor alpha-chain (CD25) expression on leukaemic blasts is predictive for outcome and level of residual disease in AML

(2009) Monique Terwijn et al.   EUROPEAN JOURNAL OF CANCER

Anthracycline Dose Intensification in Acute Myeloid Leukemia

(2009) Hugo F. Fernandez et al.   NEW ENGLAND JOURNAL OF MEDICINE